Emerald Advisers’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Emerald Advisers’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-38,490	Closed	-$2.31M	–	330
2016 Q3	$2.31M	Hold	38,490	–	–	0.1%	193
2016 Q2	$1.97M	Sell	38,490 -85,480	-69%	-$3.65M	0.09%	207
2016 Q1	$3.66M	Buy	123,970 +14,630	+13%	+$461K	0.18%	152
2015 Q4	$4.95M	Buy	+109,340	New	+$5.73M	0.23%	126
2015 Q3	–	Sell	-25,084	Closed	-$1.51M	–	352
2015 Q2	$1.51M	Sell	25,084 -15	-0.1%	-$992	0.07%	223
2015 Q1	$1.4M	Buy	+25,099	New	+$1.45M	0.07%	232

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SMV

Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers's ONCE Position: Q4 2016 in Review

Emerald Advisers sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2016, closing a stake of 38,490 shares — an estimated $2.31M sold.

Emerald Advisers first reported a position in ONCE in Q1 2015 and held it in 6 quarters. The position peaked at $4.95M in Q4 2015. 119 funds tracked by Wall St. Rank hold ONCE as of Q4 2016.

Emerald Advisers reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Emerald Advisers sold 38,490 Spark Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $2.31M.
Emerald Advisers first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 6 quarters.
Emerald Advisers's Spark Therapeutics, Inc. Common Stock position peaked at $4.95M in Q4 2015.
119 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Emerald Advisers's 13F filing for Q4 2016, filed 26 Jan 2017.